

Distinguished Oncologist Dr. Junji Furuse To Join VRise Therapeutics Scientific Advisory Board

Dr. Junji Furuse is President of Kanagawa Cancer Center, A Comprehensive Cancer Research Center and Hospital in Yokohama, Japan

CAMBRIDGE, MASSACHUSETTS, USA, August 1, 2022 /EINPresswire.com/ -- VRise Therapeutics Inc., a precision oncology company, aspiring to bring breakthrough novel therapies in otherwise undruggable targets, today announced the appointment of Junji Furuse, M.D., Ph.D. to its Scientific Advisory Board.



Dr. Furuse is a Board Certified Gastrointestinal Medical Oncologist and the current President of Kanagawa Cancer Center, Japan. He also serves as Chair of the Hepatobiliary and Pancreatic Oncology Group for the Japanese Clinical Oncology Group (JCOG), Director of the Japanese Society of Medical Oncology (JSMO) and the Director and Chair of the health insurance committee for the Japanese Pancreas Society (JPS). Dr. Furuse has made significant contributions to medical oncology, especially hepatobiliary and pancreatic cancer, and is recognized as a key opinion leader in this area.

Dr. Furuse commented: "Pancreatic cancer has an extremely dismal prognosis but is improving with progress in systemic chemotherapy. However, precision therapies targeting the KRASG12D mutation could bring revolutionary change to the current treatment regimen. I am very glad to join the VRise Scientific Advisory Board supporting the development of these important projects."

Uday Kumar S., Founder of VRise Therapeutics, Inc. commented: "Japan has an unusually high burden of pancreatic cancer, and we are excited to have such a distinguished oncologist like Dr. Furuse on our advisory board. This appointment gives VRise an opportunity to strengthen our clinical efforts and reach in Japan. We look forward to working with Dr. Furuse and JCOG to bring these incredible discoveries to patients"

About VRise Therapeutics, Inc.

VRise Therapeutics is a precision oncology company aspiring to bring transformative change to the lives of cancer patients. The company is working on novel biological targets by leveraging next generation technology and a global network to accelerate the discovery and development of breakthrough drugs.

For more information about VRise Therapeutics, visit us at www.vrisetx.com

Forward Looking Statements

This press release contains forward-looking statements regarding the business of Vrise Therapeutics, Inc. ("VRise"). Any statement describing Vrise's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of VRise's drug development pipeline, including without limitation of its KRAS G12C and KRAS G12D programs, is a forward-looking statement and should be considered an at-risk statement. VRise Therapeutics actual results or plans may differ materially from the anticipated results and expectations expressed in these forward-looking statements, due to various factors, including the risks and uncertainties inherent in biotech domain including drug discovery, clinical trials, drug development, and any commercialization and other risk factors identified from time to time in relation to the current line of business. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

VRise Therapeutics Inc makes no representations as to, and no party shall be entitled to rely upon, the legal, regulatory, or tax implications of the data and or matters referred to herein, and neither VRise Therapeutics Inc nor any of its directors, officers, employees, or agents shall incur any responsibility or liability whatsoever to any party in respect of the contents or any matters referred to in, or discussed as a result of, this presentation and/or document.

Strategy and Corporate Development

Mark Wong

VRise Therapeutics, Inc.

+1 617-682-9519

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/582832091>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.